Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

5WEW

Crystal structure of Klebsiella pneumoniae fosfomycin resistance protein (FosAKP) with inhibitor (ANY1) bound

Summary for 5WEW
Entry DOI10.2210/pdb5wew/pdb
Related5V3D 5V91 5WEP
DescriptorFosfomycin resistance protein, MANGANESE (II) ION, 6,6'-(4-nitro-1H-pyrazole-3,5-diyl)bis(3-bromopyrazolo[1,5-a]pyrimidin-2(1H)-one) (3 entities in total)
Functional Keywordsfosfomycin, fosa, fosakp, glutathione s-transferase, any1, transferase, transferase-transferase inhibitor complex, transferase/transferase inhibitor
Biological sourceKlebsiella pneumoniae 30684/NJST258_2
Total number of polymer chains8
Total formula weight135210.94
Authors
Klontz, E.H.,Sundberg, E.J. (deposition date: 2017-07-10, release date: 2018-07-18, Last modification date: 2023-10-04)
Primary citationTomich, A.D.,Klontz, E.H.,Deredge, D.,Barnard, J.P.,McElheny, C.L.,Eshbach, M.L.,Weisz, O.A.,Wintrode, P.,Doi, Y.,Sundberg, E.J.,Sluis-Cremer, N.
Small-Molecule Inhibitor of FosA Expands Fosfomycin Activity to Multidrug-Resistant Gram-Negative Pathogens.
Antimicrob. Agents Chemother., 63:-, 2019
Cited by
PubMed Abstract: The spread of multidrug or extensively drug-resistant Gram-negative bacteria is a serious public health issue. There are too few new antibiotics in development to combat the threat of multidrug-resistant infections, and consequently the rate of increasing antibiotic resistance is outpacing the drug development process. This fundamentally threatens our ability to treat common infectious diseases. Fosfomycin (FOM) has an established track record of safety in humans and is highly active against , including multidrug-resistant strains. However, many other Gram-negative pathogens, including the "priority pathogens" and , are inherently resistant to FOM due to the chromosomal gene, which directs expression of a metal-dependent glutathione -transferase (FosA) that metabolizes FOM. In this study, we describe the discovery and biochemical and structural characterization of ANY1 (3-bromo-6-[3-(3-bromo-2-oxo-1H-pyrazolo[1,5-a]pyrimidin-6-yl)-4-nitro-1H-pyrazol-5-yl]-1H-pyrazolo[1,5-a]pyrimidin-2-one), a small-molecule active-site inhibitor of FosA. Importantly, ANY1 potentiates FOM activity in representative Gram-negative pathogens. Collectively, our study outlines a new strategy to expand FOM activity to a broader spectrum of Gram-negative pathogens, including multidrug-resistant strains.
PubMed: 30642934
DOI: 10.1128/AAC.01524-18
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (3.178 Å)
Structure validation

247536

PDB entries from 2026-01-14

PDB statisticsPDBj update infoContact PDBjnumon